SCHEMBL4430432

SCHEMBL4430432

COC(=O)c1ccccc1C1CCN(CCN2C=COC(C3=CC=CC(=O)C3)=C2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 1/20 0.35
CCR5 P51681 1/20 0.35
GRM2 Q14416 1/20 0.34
RBP4 P02753 1/20 0.34
UTS2R Q9UKP6 1/20 0.34
DRD2 P14416 3/20 0.33
PRCP P42785 1/20 0.33
SLC18A3 Q16572 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
KMT2A Q03164 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
HTR2A P28223 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889118 0.90 SIGMAR1 (0.36) ALDH1A1KDM4EPRCPSLC18A3GAA
SCHEMBL4430408 0.89 UTS2R (0.37) ALDH1A1KDM4EHPGDUTS2RDRD2
SCHEMBL4429751 0.89 KCNH2 (0.37) ALDH1A1KDM4EHPGDUTS2RDRD2
SCHEMBL4890241 0.88 HPGD (0.37) ALDH1A1KDM4EHPGDUTS2RDRD2
SCHEMBL4440078 0.87 UTS2R (0.36) UTS2RDRD2HTR2ADRD3
SCHEMBL4891155 0.86 UTS2R (0.36) UTS2RPRCPMEN1KMT2AADRA1D
SCHEMBL4438087 0.86 UTS2R (0.43) UTS2RDRD2HTR2ADRD3
SCHEMBL4569627 0.86 MCHR1 (0.36) ALDH1A1HPGDUTS2RDRD2PRCP
SCHEMBL4890309 0.85 BCL3 (0.35) UTS2RMEN1KMT2ADRD3
SCHEMBL4880934 0.85 UTS2R (0.38) ALDH1A1UTS2RMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
EP-2049120-A1 UROTENSIN II RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2009-04-22 EP disclosed
US-20080039454-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-14 US disclosed
WO-2008016534-A1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039454-A1 Urotensin II receptor antagonists UTS2R, PLAUR, NTSR2 ALDH1A1 4139/4885KDM4E 4604/4885HPGD 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.